Cover Image

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

Giorgio L Colombo1, Sergio Di Matteo2, Ketty Peris3, Maria Concetta Fargnoli3, Maria Esposito4, Annamaria Mazzotta4, Sergio Chimenti41Faculty of Pharmacy, University of Pavia, Pavia, Italy; 2S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, Italy; 3Department of Dermatology, University of L&...

Full description

Saved in:

Bibliographic Details
Main Authors:	Giorgio L Colombo (Author), Sergio Di Matteo (Author), Ketty Peris (Author), Maria Concetta Fargnoli (Author), et al (Author)
Format:	Book
Published:	Dove Medical Press, 2009-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
by: Maria Elisa Mancuso, et al.
Published: (2011)

Plaque psoriasis in children and adolescents – the role of etanercept
by: Ricceri F, et al.
Published: (2012)

The CANOVA Study Real-World Evidence of Biologic Treatments in Moderate-Severe Psoriasis in Italy: A Gender Perspective
by: Delia Colombo, et al.
Published: (2022)

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
by: Emanuela Zagni, et al.
Published: (2021)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
by: Colombo GL, et al.
Published: (2018)

The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
by: Nyholm N, et al.
Published: (2023)

Etanercept in the treatment of plaque psoriasis
by: Thao U Nguyen, et al.
Published: (2009)

Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
by: Ting-Shun Wang, et al.
Published: (2013)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016)

Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation
by: Colombo GL, et al.
Published: (2012)

Psoriasis, lymphoma and etanercept: is there a correlation? Psoríase, linfoma e etanercepte: existe correlação?
by: Ludmilla Queirós Miranda, et al.
Published: (2012)

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy
by: Giorgio L Colombo, et al.
Published: (2011)

Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy
by: Antonio Maria Fea, et al.
Published: (2021)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
by: Maria Concetta Fargnoli
Published: (2019)

Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature
by: Maria Concetta Fargnoli, et al.
Published: (2023)

Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study)
by: Paolo Dapavo, et al.
Published: (2023)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
by: Jin JQ, et al.
Published: (2023)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
by: Luís Puig, et al.
Published: (2019)

Drug Utilization and Measurement of Medication Adherence: A Real World Study of Psoriasis in Italy
by: Sara Mucherino, et al.
Published: (2023)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
by: Kivelevitch D, et al.
Published: (2019)

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
by: Siegfried Segaert
Published: (2009)

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
by: Canonica GW, et al.
Published: (2020)

Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy
by: Ruggeri I, et al.
Published: (2012)

Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
by: Colombo GL, et al.
Published: (2021)

Biological therapy utilization, switching, and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy
by: Guerriero F, et al.
Published: (2017)

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
by: Selma Atalay, et al.
Published: (2020)

Clinical utility of etanercept in the treatment of arthritides in children and adolescents
by: Dore RK
Published: (2014)

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
by: Marzieh Zargaran, et al.
Published: (2021)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
by: Enrico Torre, et al.
Published: (2020)

A cost-of-illness study of spina bifida in Italy
by: Colombo GL, et al.
Published: (2013)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023)

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy
by: Rizzardini G, et al.
Published: (2012)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
by: Johansson E, et al.
Published: (2018)

Etanercept
by: Sibel Alper
Published: (2022)

<it>MC1R</it> variants predisposing to concomitant primary cutaneous melanoma in a monozygotic twin pair
by: Pellegrini Cristina, et al.
Published: (2012)

Psoríase eritrodérmica refratária em criança com excelente resposta ao etanercepte Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept
by: Naiara Abreu de Azevedo Fraga, et al.
Published: (2011)

Treatment of severe psoriasis during pregnancy and breastfeeding: A therapeutic challenging case
by: Maria Esposito, MD, et al.
Published: (2021)

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region
by: Annunziata Dattola, et al.
Published: (2024)